TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06584903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature Ramp Protocol
Description: Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Temperature Ramp Protocol
Description: Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.
Study: NCT06483230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Visual Stimulation Device
Description: The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Visual Stimulation Device
Description: The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.
Study: NCT05958082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video
Description: The educational intervention will occur with a clinical research coordinator who will be trained to educate on germline testing in prostate cancer.
Study: NCT05134935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocus Incorporated Multiple Segment (DIMS) Spectacles
Description: 18 months of therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokerathology lenses (OKL)
Description: 18 months of therapy.
Study: NCT05980260

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom-based Dosing Approach
Description: During this approach to care, all enrolled infants with NOWS at the study site will be treated with the symptom-based dosing approach if they meet the withdrawal threshold for pharmacologic treatment. Participants may receive up to 3 doses of the study site's preferred opioid during a 24-hour period to treat signs of withdrawal once the threshold for pharmacologic intervention is met. If a 4th dose is required within a 24-hour period, the study site will transition to the scheduled opioid taper algorithm used at the study site to complete the infant's pharmacologic treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom-based Dosing Approach
Description: During this approach to care, all enrolled infants with NOWS at the study site will be treated with the symptom-based dosing approach if they meet the withdrawal threshold for pharmacologic treatment. Participants may receive up to 3 doses of the study site's preferred opioid during a 24-hour period to treat signs of withdrawal once the threshold for pharmacologic intervention is met. If a 4th dose is required within a 24-hour period, the study site will transition to the scheduled opioid taper algorithm used at the study site to complete the infant's pharmacologic treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Scheduled Opioid Taper Approach
Description: During this approach to care, all enrolled infants with NOWS at the study site will be treated with the study site's usual scheduled opioid taper approach, as detailed in each site's treatment algorithm, if they meet the withdrawal threshold for pharmacologic treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Scheduled Opioid Taper Approach
Description: During this approach to care, all enrolled infants with NOWS at the study site will be treated with the study site's usual scheduled opioid taper approach, as detailed in each site's treatment algorithm, if they meet the withdrawal threshold for pharmacologic treatment.
Study: NCT04838171

Intervention type: OTHER
Intervention: White blood cell and blood collection
Description: Mononucleocytes will be collected via apheresis
Study: NCT05014256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS Health System Outreach intervention
Description: STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
Study: NCT04855552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight-loss Program Via Telehealth
Description: Investigators will use a manual based on the DPP, as adapted previously for the endometrial cancer population and now adapted for breast cancer survivors. Dr.Courtney McCuen-Wurst, has extensive experience in working with persons with overweight and obesity with medical comorbidities. She also has experience leading group interventions at our Center via telehealth. The content of the sessions addresses the domains associated with behavioral weight management including nutrition, exercise, stress and emotion management, and lifestyle modification strategies (to improve adherence to the diet and activity plan). Participants will monitor energy intake and physical activity daily to help them achieve recommended calorie and activity goals. Self-monitoring will be encouraged online with MyFitnessPal.com, which will be shared with the study staff to increase accountability and provide opportunity for feedback to participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight-Loss Program Via Telehealth - Weight Measures
Description: Each participant will also be mailed a digital scale (Eat Smart) so they can weigh themselves each week and report their weight to the group leader; patients will be encouraged to take a picture of their weight on the scale after they step off (the number remains for 3-seconds) and send the picture to Dr. McCuen-Wurst. Participants will be encouraged to start with at least 1-minutes of moderately vigorous physical activity (e.g. brisk walking, swimming), at least five days per week, building up to at least 30-minutes per day (150-minutes per week) by week-6.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Validated Surveys of Patient-Reported Outcomes
Description: The following surveys will be completed by participants pre- and post-intervention:~* COH-QOL Instrument - Breast Cancer Patient (QOL-BC)~* International Physical Activity Questionnaire (IPAQ) Short Form~* Patient Health Questionnaire (PHQ-9) (Depression)~* Acceptability of Intervention Measure~The following survey will be completed post-intervention~• Exit interview regarding acceptability of the program.~The following measurements/clinical tests results will be collected and compared pre- and post-intervention:~* Anthropometric measurements: height (self-report); weight (as measured on scale provided by study)~* Mammographic breast density estimated in annual clinical mammogram
Study: NCT06599736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RhinAer Stylus
Description: The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG1393, CAT1394), which is a 510(k) cleared (FDA - K221907) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy is also cleared for use in the US (FDA - K162810).
Study: NCT06651749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol injection
Description: hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol injection
Description: hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.
Study: NCT05099770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Participants will have a kidney biopsy followed 14 weeks later with a REACT injection into the biopsied kidney, then, another 12 weeks (+28 days) later a REACT injection into their contralateral kidney.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Participants will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 12 weeks (+28 days) after the first sham procedure.
Study: NCT06599827

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: moderately hypofractionated radiotherapy
Description: 35 Gy in 10 fractions to mesorectal and metastatic lymph nodes, and 30 Gy in 10 fractions to pelvic lymphatic drainage area, weekly over 5 days at 3-3.5 Gy/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: CapeOx-Capecitabine 1000 mg/m² orally twice daily (days 1-14, every 21 days) + Oxaliplatin 130 mg/m² IV (day 1, every 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunotherapy
Description: Serplulimab 300 mg IV infusion on day 1 every 21 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) surgery
Description: Total mesorectal excision (TME) surgery assessment post 3 cycles of chemotherapy and immunotherapy; eligible patients undergo TME surgery.
Study: NCT06597851

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermodilution based assessment of coronary microcirculation
Description: Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic Clamp test
Description: Infusion of insulin and glucose adjusting rate of glucose infusion to maintaine plasma glucose around 90 mg/dL by monitoring plasma glucose levels every 5-10 minutes
Study: NCT06612320

Intervention type: BEHAVIORAL
Intervention: Questionnaire about acceptance
Description: Questionnaire about acceptance

Intervention type: BEHAVIORAL
Intervention: Questionnaire about refusal
Description: Questionnaire about refusal
Study: NCT06595082

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4-week lupins in brine consumption
Description: Volunteers were asked to consume lupins in brine for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4-week lupins in brine consumption and dietary suggestion
Description: Volunteers were asked to consume lupins in brine for 4 weeks and refrain to two servings per week of meat or processed meat or cheese.
Study: NCT06593171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring program
Description: This three-session mentoring program is based on experiential learning and has been validated and adapted to our country. The mentors, professionals with lived experience in mental health, will provide knowledge and experiences to the students through direct contact sessions in the classroom, focusing especially on the processes of recovery and self-determination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (placebo) group
Description: This group will not receive any intervention. However, they will be invited to participate in stigma education after the study is completed.
Study: NCT06701864

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: Identification of the cricothyroid membrane using PALPATION, a procedure used to prepare for front of neck airway access

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Identification of the cricothyroid membrane, using ULTRASONOGRAPHY with either the String of pearls or TACA aproach as chosen by the participant , a procedure used to prepare for front of neck airway access
Study: NCT06704373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracal manipulation
Description: Thoracal manipulation will be applied only one session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both groups will perform the same postural exercises, which will be applied twice a week for 4 weeks. The intervention group will receive thoracic manipulation for one session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will perform the same postural exercises, which will be applied twice a week for 4 weeks. The intervention group will receive thoracic manipulation for one session.
Study: NCT06704282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Mindfulness Meditation Program
Description: A 15-minute guided mindfulness meditation session conducted in a virtual reality environment to enhance stress reduction and mindfulness.
Study: NCT06705010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of new pulse sequence package SIGNATURES2023 to healthy controls
Description: One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 100 healthy subjects to determined reference metabolite maps of the whole brain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of new pulse sequence package SIGNATURES2023 to 4 groups of patients (pilot)
Description: One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 4 time 10 patients with AD, MCI, DM and HGCS to determine metabolite maps of the whole brain.
Study: NCT06705205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAS video
Description: The intervention is a short, animated storytelling video, with soundtrack, aimed at reducing addiction stigma.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAS video
Description: The intervention is a short, animated storytelling video, with soundtrack, aimed at reducing addiction stigma.
Study: NCT06706024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Patients Under Hemodialysis
Study: NCT06705699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urethral mobilisation
Description: Involves mobilizing the urethral tube proximally and advancing it distally to the glans. The urethra is repositioned and sutured at the neomeatal position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mathieu
Description: Utilizes a perimeatal-based flap, which is flipped up to create the neourethra.
Study: NCT06705036

Intervention type: OTHER
Intervention: surgery
Description: Samples were obtained from patients by surgical excision and matched into groups

Intervention type: OTHER
Intervention: surgery
Description: Samples were obtained from patients by surgical excision and matched into groups
Study: NCT06705387

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Subcutaneous injection of 300mg per week for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.
Study: NCT06704243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: The intervention will be a monthly online AYA peer support group (1 hour) that will run for six months via Microsoft Teams.~In an effort to evaluate a patient-driven real-world intervention, the support group has been designed with the following features: 1) participants will be asked to commit for a six month period, but are able to miss sessions if necessary; and, 2) each session will be facilitated by a Nurse Practitioner and Social Worker from the Allo-HSCT program, but the topics of discussion will be determined by the AYA participants present at each session. Participants in the group will then be invited to share their thoughts and experiences about these topics, with as much information as they feel comfortable.
Study: NCT04839705

Intervention type: DEVICE
Group type: OTHER
Intervention: WEB
Description: Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~Other Names:~• WEB Aneurysm Embolization Device
Study: NCT03727815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Pain Management Arm
Description: Mindfulness Pain Management intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the pain management mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Self Esteem Arm
Description: Mindfulness Self Esteem intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the self esteem mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
Study: NCT04875884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified MRI
Description: A technical modification to the standard MRI which only affects radiofrequency pulse polarization attempting to optimize the image quality. All other factors, including pulse sequence parameters, and patient and coil positioning is similar to that of the standard MRI.
Study: NCT06349798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a similer bolus every 4 h for 24 h (6 injections in total) + continuous intravenous infusion of placebo (2 mL/h saline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a bolus of placebo every 4 h for 24 h (6 injections in total) + continuous infusion of 100 mg nefopam over 24 h (in 48 mL saline, 2 mL/h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)
Study: NCT05736874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study: NCT06525428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab
Description: First-line standard systemic therapies in cohort A include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only), FOLFIRINOX+ bevacizumab.~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.~Toripalimab will be given at 240 mg q3w. Radiotherapy regimes include 4-8 fractions of 4-12Gy via SABR or hypofractionated radiotherapy (HFRT) and 5 fractions of 0.5-2Gy via LDRT
Study: NCT05826912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Capsule, 80 mg/day, with no loading dose, for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline Hydrochloride
Description: Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan Cilexetil
Description: Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, 2x/day for 28 days
Study: NCT06327100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Given by PO
Study: NCT05732116

Intervention type: OTHER
Intervention: PTSD
Description: Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.